What is claimed:

1. A nucleic acid molecule encoding a Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) spike antigen, the nucleic acid molecule comprising:
   a nucleic acid sequence having at least 99% identity over an entire length of the nucleic acid sequence set forth in nucleotides 55 to 3837 of SEQ ID NO: 2;
   a nucleic acid sequence having at least 99% identity over an entire length of SEQ ID NO: 2;
   the nucleic acid sequence of nucleotides 55 to 3837 of SEQ ID NO: 2; or
   the nucleic acid sequence of SEQ ID NO: 2.

2. An expression vector comprising the nucleic acid molecule according to claim 1, said vector optionally comprising the nucleic acid sequence of SEQ ID NO: 3.

3. An immunogenic composition comprising an effective amount of the expression vector according claim 2 and a pharmaceutically acceptable excipient.

4. The immunogenic composition according to claim 3 wherein the pharmaceutically acceptable excipient comprises a buffer, optionally saline-sodium citrate buffer.

5. The immunogenic composition of claim 4, wherein the composition comprises 10 mg of the vector per milliliter of saline-sodium citrate buffer.

6. The immunogenic composition according to any one of claims 3-5, further comprising an adjuvant.

7. Use of the immunogenic composition of any one of claims 3-6 in the manufacture of a medicament for inducing an immune response against Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) in a subject in need thereof.

8. Use of the immunogenic composition of any one of claims 3-6 in the manufacture of a medicament for protecting a subject from infection with Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV- 2).

9. Use of the immunogenic composition of any one of claims 3-6 in the manufacture of a medicament

for treating a subject in need thereof against Severe Acute Respiratory Syndrome coronavirus 2 (SARS- CoV-2) infection.

10. The use of any one of claims 7-9 in combination with at least one additional agent for the treatment of SARS-CoV-2 infection or the treatment or prevention of a disease or disorder associated with SARS-CoV-2 infection.

11. The use of any one of claims 7-10 , wherein the immunogenic composition is formulated for administration by at least one of electroporation and injection.

12. The use of claim 11, wherein the immunogenic composition is formulated for parenteral administration followed by electroporation.

13. The use of any one of claims 7 to 12, wherein the immunogenic composition is formulated at a an initial dose of about 0.5 mg to about 2.0 mg of the vector, optionally at a dose of 0.5 mg, 1.0 mg, or 2.0 mg of the vector.

14. The use of any one of claims 7 to 13, wherein the immunogenic composition is INO- 4800 or a biosimilar thereof.

15. The immunogenic composition of any one of claims 3-6 for use in therapy.

16. The vector of claim 2 for use as a medicament.

17. Use of the vector of claim 2 in the preparation of a medicament for treating or protecting against infection with Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2).